Publication:

Antidepressant medications: a comprehensive review of efficacy, safety, and future directions

Depression is a disabling psychiatric disorder that affects emotional, cognitive, and physical functioning worldwide. Pharmacotherapy remains the cornerstone of treatment; however, limitations such as delayed onset, adverse effects, and treatment resistance continue to challenge clinical management. Recent advances in psychopharmacology, including rapid-acting agents, multimodal antidepressants, and pharmacogenomic-guided therapy, offer new possibilities for improving outcomes. A systematic review of PubMed, Scopus, and Web of Science databases was conducted for studies published between 2000 and 2024. Using preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines, 35 peer-reviewed articles—including randomized controlled trials, meta-analyses, and systematic reviews—were selected. Data on mechanisms, efficacy, safety, and emerging therapies were qualitatively analyzed to synthesize current evidence on antidepressant pharmacotherapy. Conventional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) remain effective first-line agents, though approximately 30–40% of patients exhibit inadequate response. Recent findings highlight the efficacy of novel treatments like ketamine, esketamine, and vortioxetine, which demonstrate rapid symptom relief and cognitive benefits. Personalized medicine and pharmacogenomics are emerging as valuable tools to optimize drug selection and minimize side effects. Additionally, controlled psychedelic-assisted therapies show promise for treatment-resistant depression. Antidepressant therapy is undergoing a paradigm shift toward precision psychiatry. Integration of rapid-acting agents, multimodal mechanisms, and personalized approaches may enhance efficacy, tolerability, and patient-centered outcomes. Continued research into novel targets and individualized treatment strategies is essential to advance the management of depressive disorders.